title: Ethanol alters the effect of kappa receptor ligands on dopamine release in the nucleus accumbens.
abstract: Repeated exposure to ethanol has previously been shown to induce alterations in both midbrain dopamine and dynorphin systems. The aim of this study was to investigate functional changes in the sensitivity of dynorphin/kappa-receptor systems following repeated ethanol administration, using dopamine as an indirect marker. The effects of kappa-opioid receptor ligands on dopamine release in the rat nucleus accumbens were investigated following repeated ethanol administration (2 g/kg body weight, twice daily for 7 days). The selective kappa-receptor agonist U50, 488H reduced dopamine levels in both ethanol- and saline-treated animals, although the decline had a later onset and lasted shorter in the ethanol-treated group. Nor-binaltorphimine, a kappa-antagonist, produced a significant increase of dopamine in ethanol-treated rats, but lacked effect in the saline-treated group. This change in responsiveness of dopamine neurons following repeated ethanol administration could be related to changes in the sensitivity of kappa-receptor systems and/or an increase in dynorphin tone in the nucleus accumbens.
authors.affiliation: Karolinska Institutet, Department of Clinical Neuroscience, CMM L8:01, Karolinska, Hospital, S-171 76 Stockholm, Sweden.
authors.forename: Sara
authors.initials: S
authors.lastname: Lindholm
authors.forename: Asa
authors.initials: A
authors.lastname: Rosin
authors.forename: Ingrid
authors.initials: I
authors.lastname: Dahlin
authors.forename: Jeanette
authors.initials: J
authors.lastname: Georgieva
authors.forename: Johan
authors.initials: J
authors.lastname: Franck
mesh_terms: D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer / Q000494:pharmacology; D000818:Animals; D000697:Central Nervous System Stimulants / Q000008:administration & dosage / Q000494:pharmacology*; D004298:Dopamine / Q000378:metabolism*; D004334:Drug Administration Schedule; D004347:Drug Interactions; D004361:Drug Tolerance / Q000502:physiology*; D004399:Dynorphins / Q000819:agonists / Q000037:antagonists & inhibitors; D000431:Ethanol / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D009271:Naltrexone / Q000031:analogs & derivatives / Q000494:pharmacology; D009714:Nucleus Accumbens / Q000187:drug effects* / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D017473:Receptors, Opioid, kappa / Q000187:drug effects*
chemical_list: D000697:Central Nervous System Stimulants; D017473:Receptors, Opioid, kappa; C051844:norbinaltorphimine; D000431:Ethanol; D009271:Naltrexone; D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; D004399:Dynorphins; D004298:Dopamine